The pathogenesis, diagnosis and treatment of Raynaud phenomenon, Nat Rev Rheumatol. 2012 août, vol.8, issue.8, pp.469-79 ,
Geographic variation in the prevalence of Raynaud's phenomenon: a 5 region comparison, J Rheumatol, vol.24, issue.5, pp.879-89, 1997. ,
Drug-induced Raynaud's phenomenon: beyond ?-adrenoceptor blockers, Br J Clin Pharmacol, vol.82, issue.1, pp.6-16, 2016. ,
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon, Arthritis Rheum, vol.46, issue.9, pp.2410-2430, 2002. ,
Surrogate endpoints in clinical trials: definition and operational criteria, Stat Med, vol.8, issue.4, pp.431-471, 1989. ,
The validation of surrogate endpoints in meta-analyses of randomized experiments, Biostatistics, vol.1, issue.1, pp.49-67, 2000. ,
Impaired transient vasodilation and increased vasoconstriction to digital local cooling in primary Raynaud's phenomenon, Am J Physiol Heart Circ Physiol, vol.301, issue.2, pp.324-354, 2011. ,
, Validity of surrogate endpoints in oncology Executive summary of rapid report A10-05, Version 1.1. In: Institute for Quality and Efficiency in Health Care: Executive Summaries
Institute for Quality and Efficiency in Health Care ,
Clinical Trials in Raynaud Phenomenon: A spoonful of sugar (pill) makes the medicine go down (in flames), 2017. ,
Reproducibility of a local cooling test to assess microvascular function in human skin, Microvasc Res, vol.79, issue.1, pp.34-43, 2010. ,
N-of-1 trials to enhance patient outcomes: identifying effective therapies and reducing harms, one patient at a time, J Clin Epidemiol, vol.76, pp.6-8, 2016. ,